Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINA6 | P08185 | 6/20 | 0.80 |
| ▸ | FNTA | P49354 | 1/20 | 0.75 |
| ▸ | FNTB | P49356 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.72 |
| ▸ | LMNA | P02545 | 8/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.72 |
| ▸ | SHBG | P04278 | 5/20 | 0.72 |
| ▸ | MAPT | P10636 | 5/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.67 |
| ▸ | TSHR | P16473 | 4/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.67 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.67 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.67 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.67 |
| ▸ | SLC22A3 | O75751 | 2/20 | 0.67 |
| ▸ | THPO | P40225 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13026136 | 1.00 | SERPINA6 (0.80) | SERPINA6FNTAFNTBSMN1; SMN2LMNA | |
| SCHEMBL14382323 | 1.00 | SERPINA6 (0.80) | SERPINA6FNTAFNTBSMN1; SMN2LMNA | |
| SCHEMBL141611 | 1.00 | SERPINA6 (0.80) | SERPINA6FNTAFNTBSMN1; SMN2LMNA | |
| SCHEMBL141610 | 1.00 | SERPINA6 (0.80) | SERPINA6FNTAFNTBSMN1; SMN2LMNA | |
| SCHEMBL9073248 | 0.91 | SERPINA6 (0.79) | SERPINA6FNTAFNTBSMN1; SMN2LMNA | |
| SCHEMBL8751542 | 0.90 | FNTA (0.81) | SERPINA6FNTAFNTBSMN1; SMN2LMNA | |
| SCHEMBL668966 | 0.89 | SERPINA6 (1.00) | SERPINA6FNTAFNTBSMN1; SMN2LMNA | |
| SCHEMBL15904593 | 0.89 | SERPINA6 (1.00) | SERPINA6FNTAFNTBSMN1; SMN2LMNA | |
| SCHEMBL14525642 | 0.89 | SERPINA6 (1.00) | SERPINA6FNTAFNTBSMN1; SMN2LMNA | |
| SCHEMBL15920543 | 0.89 | SERPINA6 (1.00) | SERPINA6FNTAFNTBSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12553041-B2 | Formulations and doses of pegylated uricase | Cartesian Therapeutics Inc. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260021113-A1 | INTRAVITREAL CORTICOSTEROID EXTENDED RELEASE IMPLANT AND METHODS OF USE | EYEDEA BIO LLC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12433900-B2 | Intravitreal corticosteroid extended release implant and methods of use | EYEDEA BIO, LLC (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4599848-A2 | METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTI-INFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT | Cartesian Therapeutics, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4595981-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING AN ANTI-INTEGRIN V 6 BINDING ANTIBODY | Elands, Jack (BE) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025132907-A1 | NOVEL ANTIBODY-DRUG CONJUGATES COMPRISING AN ANTI-(TCR)-CD3-COMPLEX BINDING ANTIBODY | ADCYTHERIX SAS (FR) | 2025-06-26 | — | — | WO | disclosed |
| EP-4574174-A1 | NOVEL ANTIBODY-DRUG CONJUGATES COMPRISING AN ANTI-(TCR)-CD3-COMPLEX BINDING ANTIBODY | Elands, Jack (BE) | 2025-06-25 | — | — | EP | disclosed |
| EP-3592389-B1 | METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTI-INFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT | CARTESIAN THERAPEUTICS INC (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20250108094-A1 | METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTI-INFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT | CARTESIAN THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | US | disclosed |
| US-20250090451-A1 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | CARTESIAN THERAPEUTICS, INC. (US) | 2025-03-20 | — | — | US | disclosed |
| US-20180168490-A1 | INGESTIBLE DEVICE AND ASSOCIATED METHODS | GLAS USA LLC | 2018-06-21 | — | — | US | disclosed |
| WO-2018112389-A1 | INGESTIBLE DEVICE AND ASSOCIATED METHODS | PROGENITY INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018112441-A1 | INGESTIBLE DEVICE AND ASSOCIATED METHODS | PROGENITY INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018111326-A1 | METHODS AND INGESTIBLE DEVICES FOR THE REGIO-SPECIFIC RELEASE OF IMMUNOSUPPRESSANTS AT THE SITE OF GASTROINTESTINAL TRACT DISEASE | PROGENITY INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018112425-A1 | INGESTIBLE DEVICE AND ASSOCIATED METHODS | PROGENITY INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018106931-A1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | PROGENITY INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018106933-A1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | PROGENITY INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018106945-A1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | PROGENITY INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| US-20180164221-A1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | BT BIDCO LLC | 2018-06-14 | — | — | US | disclosed |
| WO-2018106959-A1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | PROGENITY INC. (US) | 2018-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12553041-B2 | Formulations and doses of pegylated uricase | PON1, PNP, PCSK9 | SERPINA6 43/4885FNTA 1204/4885FNTB 2599/4885 |
| US-20260021113-A1 | INTRAVITREAL CORTICOSTEROID EXTENDED RELEASE IMPLANT AND METHODS OF USE | NR3C2, NR3C1, STARD3 | SERPINA6 173/4885FNTA 1154/4885FNTB 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.